Artículos de revistas sobre el tema "Vaccine elicited antibodies"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Vaccine elicited antibodies".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Willis, Elinor, Norbert Pardi, Kaela Parkhouse, Barbara L. Mui, Ying K. Tam, Drew Weissman y Scott E. Hensley. "Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice". Science Translational Medicine 12, n.º 525 (8 de enero de 2020): eaav5701. http://dx.doi.org/10.1126/scitranslmed.aav5701.
Texto completoGupta, Rajesh K., David N. Taylor, Dolores A. Bryla, John B. Robbins y Shousun C. Szu. "Phase 1 Evaluation of Vibrio choleraeO1, Serotype Inaba, Polysaccharide-Cholera Toxin Conjugates in Adult Volunteers". Infection and Immunity 66, n.º 7 (1 de julio de 1998): 3095–99. http://dx.doi.org/10.1128/iai.66.7.3095-3099.1998.
Texto completoGreaney, Allison J., Andrea N. Loes, Lauren E. Gentles, Katharine H. D. Crawford, Tyler N. Starr, Keara D. Malone, Helen Y. Chu y Jesse D. Bloom. "Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection". Science Translational Medicine 13, n.º 600 (8 de junio de 2021): eabi9915. http://dx.doi.org/10.1126/scitranslmed.abi9915.
Texto completoHarris, Shannon L., Adam Finn y Dan M. Granoff. "Disparity in Functional Activity between Serum Anticapsular Antibodies Induced in Adults by Immunization with an Investigational Group A and C Neisseria meningitidis-Diphtheria Toxoid Conjugate Vaccine and by a Polysaccharide Vaccine". Infection and Immunity 71, n.º 6 (junio de 2003): 3402–8. http://dx.doi.org/10.1128/iai.71.6.3402-3408.2003.
Texto completoNuñez, Ivette A., Ying Huang y Ted M. Ross. "Next-Generation Computationally Designed Influenza Hemagglutinin Vaccines Protect against H5Nx Virus Infections". Pathogens 10, n.º 11 (20 de octubre de 2021): 1352. http://dx.doi.org/10.3390/pathogens10111352.
Texto completoKoeberling, Oliver, Isabel Delany y Dan M. Granoff. "A Critical Threshold of Meningococcal Factor H Binding Protein Expression Is Required for Increased Breadth of Protective Antibodies Elicited by Native Outer Membrane Vesicle Vaccines". Clinical and Vaccine Immunology 18, n.º 5 (2 de marzo de 2011): 736–42. http://dx.doi.org/10.1128/cvi.00542-10.
Texto completoSalat, Jiri, Petra Strakova y Daniel Ruzek. "Dynamics of Whole Virus and Non-Structural Protein 1 (NS1) IgG Response in Mice Immunized with Two Commercial Tick-Borne Encephalitis Vaccines". Vaccines 10, n.º 7 (23 de junio de 2022): 1001. http://dx.doi.org/10.3390/vaccines10071001.
Texto completoDapporto, Francesca, Serena Marchi, Margherita Leonardi, Pietro Piu, Piero Lovreglio, Nicola Decaro, Nicola Buonvino et al. "Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination". Journal of Immunology Research 2022 (31 de agosto de 2022): 1–9. http://dx.doi.org/10.1155/2022/4813199.
Texto completoWarner, Nikole L. y Kathryn M. Frietze. "Development of Bacteriophage Virus-Like Particle Vaccines Displaying Conserved Epitopes of Dengue Virus Non-Structural Protein 1". Vaccines 9, n.º 7 (2 de julio de 2021): 726. http://dx.doi.org/10.3390/vaccines9070726.
Texto completoGiles, Brendan M., Stephanie J. Bissel, Dilhari R. DeAlmeida, Clayton A. Wiley y Ted M. Ross. "Antibody Breadth and Protective Efficacy Are Increased by Vaccination with Computationally Optimized Hemagglutinin but Not with Polyvalent Hemagglutinin-Based H5N1 Virus-Like Particle Vaccines". Clinical and Vaccine Immunology 19, n.º 2 (21 de diciembre de 2011): 128–39. http://dx.doi.org/10.1128/cvi.05533-11.
Texto completoVisciano, Maria Luisa, Aakash Mahant Mahant, Carl Pierce, Richard Hunte y Betsy C. Herold. "Antibodies Elicited in Response to a Single Cycle Glycoprotein D Deletion Viral Vaccine Candidate Bind C1q and Activate Complement Mediated Neutralization and Cytolysis". Viruses 13, n.º 7 (30 de junio de 2021): 1284. http://dx.doi.org/10.3390/v13071284.
Texto completoHeile, Jens M., Yiu-Lian Fong, Domenico Rosa, Kim Berger, Giulietta Saletti, Susanna Campagnoli, Giuliano Bensi et al. "Evaluation of Hepatitis C Virus Glycoprotein E2 for Vaccine Design: an Endoplasmic Reticulum-Retained Recombinant Protein Is Superior to Secreted Recombinant Protein and DNA-Based Vaccine Candidates". Journal of Virology 74, n.º 15 (1 de agosto de 2000): 6885–92. http://dx.doi.org/10.1128/jvi.74.15.6885-6892.2000.
Texto completoWaickman, Adam T., Joseph Lu, Corey Chase, Hengsheng Fang, Erinn McDowell, Erin Bingham, Jeffrey Bogart, Stephen Graziano, Stephen J. Thomas y Teresa Gentile. "Systemic Cancer Therapy Does Not Significantly Impact Early Vaccine-Elicited SARS-CoV-2 Immunity in Patients with Solid Tumors". Vaccines 10, n.º 5 (9 de mayo de 2022): 738. http://dx.doi.org/10.3390/vaccines10050738.
Texto completoHu, Mary C., Michael A. Walls, Steven D. Stroop, Mark A. Reddish, Bernard Beall y James B. Dale. "Immunogenicity of a 26-Valent Group A Streptococcal Vaccine". Infection and Immunity 70, n.º 4 (abril de 2002): 2171–77. http://dx.doi.org/10.1128/iai.70.4.2171-2177.2002.
Texto completoBasha, Saleem, Staci Hazenfeld, Rebecca Brady y Ramu Subbramanian. "Domain-specific variation in hemagglutinin-specific T-cell responses elicited by licensed seasonal influenza vaccines (106.11)". Journal of Immunology 186, n.º 1_Supplement (1 de abril de 2011): 106.11. http://dx.doi.org/10.4049/jimmunol.186.supp.106.11.
Texto completoChing, Lance K., Giorgos Vlachogiannis, Katherine A. Bosch y Leonidas Stamatatos. "The First Hypervariable Region of the gp120 Env Glycoprotein Defines the Neutralizing Susceptibility of Heterologous Human Immunodeficiency Virus Type 1 Isolates to Neutralizing Antibodies Elicited by the SF162gp140 Immunogen". Journal of Virology 82, n.º 2 (14 de noviembre de 2007): 949–56. http://dx.doi.org/10.1128/jvi.02143-07.
Texto completoChandrasekar, Shaswath S., Yashdeep Phanse, Rachel E. Hildebrand, Mostafa Hanafy, Chia-Wei Wu, Chungyi H. Hansen, Jorge E. Osorio, M. Suresh y Adel M. Talaat. "Localized and Systemic Immune Responses against SARS-CoV-2 Following Mucosal Immunization". Vaccines 9, n.º 2 (6 de febrero de 2021): 132. http://dx.doi.org/10.3390/vaccines9020132.
Texto completoTurner, Hannah L., Raiees Andrabi, Christopher A. Cottrell, Sara T. Richey, Ge Song, Sean Callaghan, Fabio Anzanello et al. "Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization". Science Advances 7, n.º 31 (julio de 2021): eabh2791. http://dx.doi.org/10.1126/sciadv.abh2791.
Texto completoMadani, Navid, Amy M. Princiotto, David Easterhoff, Todd Bradley, Kan Luo, Wilton B. Williams, Hua-Xin Liao et al. "Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds". Journal of Virology 90, n.º 10 (9 de marzo de 2016): 5031–46. http://dx.doi.org/10.1128/jvi.03211-15.
Texto completoMurji, Amyn A., Juliana S. Qin, Tandile Hermanus, Lynn Morris y Ivelin S. Georgiev. "Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms". Viruses 13, n.º 7 (2 de julio de 2021): 1296. http://dx.doi.org/10.3390/v13071296.
Texto completoLian, Ying, Indresh Srivastava, V. Rául Gómez-Román, Jan zur Megede, Yide Sun, Elaine Kan, Susan Hilt et al. "Evaluation of Envelope Vaccines Derived from the South African Subtype C Human Immunodeficiency Virus Type 1 TV1 Strain". Journal of Virology 79, n.º 21 (1 de noviembre de 2005): 13338–49. http://dx.doi.org/10.1128/jvi.79.21.13338-13349.2005.
Texto completoMaciejewski, Sonia, Tracy J. Ruckwardt, Kaitlyn M. Morabito, Bryant M. Foreman, Katherine E. Burgomaster, David N. Gordon, Rebecca S. Pelc et al. "Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality". Science Translational Medicine 12, n.º 547 (10 de junio de 2020): eaaw9066. http://dx.doi.org/10.1126/scitranslmed.aaw9066.
Texto completoBryan, J. T., J. F. Smith, W. Ruiz, M. K. Brownlow, M. J. Brown y M. T. Esser. "Evaluation of antibodies induced by an HPV vaccine to cross-neutralize pseudovirions of vaccine-related HPV types". Journal of Clinical Oncology 24, n.º 18_suppl (20 de junio de 2006): 15008. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.15008.
Texto completoDangi, Tanushree, Nicole M. Palacio, Sarah Sanchez y Pablo Penaloza-MacMaster. "Characterization of cross-reactive immunity following coronavirus vaccination or natural infection". Journal of Immunology 206, n.º 1_Supplement (1 de mayo de 2021): 103.13. http://dx.doi.org/10.4049/jimmunol.206.supp.103.13.
Texto completoZost, Seth J., Kaela Parkhouse, Megan E. Gumina, Kangchon Kim, Sebastian Diaz Perez, Patrick C. Wilson, John J. Treanor, Andrea J. Sant, Sarah Cobey y Scott E. Hensley. "Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains". Proceedings of the National Academy of Sciences 114, n.º 47 (6 de noviembre de 2017): 12578–83. http://dx.doi.org/10.1073/pnas.1712377114.
Texto completoAbd Alla, Mohamed D., Gary L. White, Tyson B. Rogers, Max E. Cary, David W. Carey y Jonathan I. Ravdin. "Adherence-Inhibitory Intestinal Immunoglobulin A Antibody Response in Baboons Elicited by Use of a Synthetic Intranasal Lectin-Based Amebiasis Subunit Vaccine". Infection and Immunity 75, n.º 8 (25 de mayo de 2007): 3812–22. http://dx.doi.org/10.1128/iai.00341-07.
Texto completoNeerukonda, Sabari Nath, Russell Vassell, Sabrina Lusvarghi, Richard Wang, Fernando Echegaray, Lisa Bentley, Ann E. Eakin et al. "SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity". Viruses 13, n.º 12 (11 de diciembre de 2021): 2485. http://dx.doi.org/10.3390/v13122485.
Texto completoNagashima, Kaito A. y Jarrod J. Mousa. "Next-Generation Influenza HA Immunogens and Adjuvants in Pursuit of a Broadly Protective Vaccine". Viruses 13, n.º 4 (24 de marzo de 2021): 546. http://dx.doi.org/10.3390/v13040546.
Texto completoLuo, Deyan, Bing Ni, Peng Li, Wei Shi, Songle Zhang, Yue Han, Liwei Mao, Yangdong He, Yuzhang Wu y Xiliang Wang. "Protective Immunity Elicited by a Divalent DNA Vaccine Encoding Both the L7/L12 and Omp16 Genes of Brucella abortus in BALB/c Mice". Infection and Immunity 74, n.º 5 (mayo de 2006): 2734–41. http://dx.doi.org/10.1128/iai.74.5.2734-2741.2006.
Texto completoPenezina, Oksana, Neil X. Krueger, Isaac R. Rodriguez-Chavez, Michael P. Busch, John Hural, Jerome H. Kim, Robert J. O'Connell et al. "Performance of a Redesigned HIV Selectest Enzyme-Linked Immunosorbent Assay Optimized To Minimize Vaccine-Induced Seropositivity in HIV Vaccine Trial Participants". Clinical and Vaccine Immunology 21, n.º 3 (8 de enero de 2014): 391–98. http://dx.doi.org/10.1128/cvi.00748-13.
Texto completoRiddle, Mark S., Robert W. Kaminski, Claudio Di Paolo, Chad K. Porter, Ramiro L. Gutierrez, Kristen A. Clarkson, Hailey E. Weerts et al. "Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study". Clinical and Vaccine Immunology 23, n.º 12 (31 de agosto de 2016): 908–17. http://dx.doi.org/10.1128/cvi.00224-16.
Texto completoChou, Ai-Hsiang, Chia-Chyi Liu, Jui-Yuan Chang, Shu-Pei Lien, Meng-Shin Guo, Hau-Pong Tasi, Kuang-Nan Hsiao et al. "Immunological Evaluation and Comparison of Different EV71 Vaccine Candidates". Clinical and Developmental Immunology 2012 (2012): 1–8. http://dx.doi.org/10.1155/2012/831282.
Texto completoMancini, Francesca, Francesca Micoli y Omar Rossi. "Setup and Characterization of a High-Throughput Luminescence-Based Serum Bactericidal Assay (L-SBA) to Determine Functionality of Human Sera against Shigella flexneri". BioTech 11, n.º 3 (27 de julio de 2022): 29. http://dx.doi.org/10.3390/biotech11030029.
Texto completoVerma, Anita, Miriam M. Ngundi y Drusilla L. Burns. "Mechanistic Analysis of the Effect of Deamidation on the Immunogenicity of Anthrax Protective Antigen". Clinical and Vaccine Immunology 23, n.º 5 (24 de febrero de 2016): 396–402. http://dx.doi.org/10.1128/cvi.00701-15.
Texto completoSarker, Protim, Evana Akhtar, Rakib Ullah Kuddusi, Mohammed Mamun Alam, Md Ahsanul Haq, Md Biplob Hosen, Bikash Chandra Chanda et al. "Comparison of the Immune Responses to COVID-19 Vaccines in Bangladeshi Population". Vaccines 10, n.º 9 (8 de septiembre de 2022): 1498. http://dx.doi.org/10.3390/vaccines10091498.
Texto completoArevalo, Claudia P., Marcus J. Bolton, Valerie Le Sage, Naiqing Ye, Colleen Furey, Hiromi Muramatsu, Mohamad-Gabriel Alameh et al. "A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes". Science 378, n.º 6622 (25 de noviembre de 2022): 899–904. http://dx.doi.org/10.1126/science.abm0271.
Texto completoKamei, Akinobu, Yamara S. Coutinho-Sledge, Joanna B. Goldberg, Gregory P. Priebe y Gerald B. Pier. "Mucosal Vaccination with a Multivalent, Live-Attenuated Vaccine Induces Multifactorial Immunity againstPseudomonas aeruginosaAcute Lung Infection". Infection and Immunity 79, n.º 3 (13 de diciembre de 2010): 1289–99. http://dx.doi.org/10.1128/iai.01139-10.
Texto completoHuang, Ying, Monique S. França, James D. Allen, Hua Shi y Ted M. Ross. "Next Generation of Computationally Optimized Broadly Reactive HA Vaccines Elicited Cross-Reactive Immune Responses and Provided Protection against H1N1 Virus Infection". Vaccines 9, n.º 7 (16 de julio de 2021): 793. http://dx.doi.org/10.3390/vaccines9070793.
Texto completoCheng, Cheng, Jason G. D. Gall, Martha Nason, C. Richter King, Richard A. Koup, Mario Roederer, M. Juliana McElrath et al. "Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or Immunization". Journal of Virology 84, n.º 1 (21 de octubre de 2009): 630–38. http://dx.doi.org/10.1128/jvi.00866-09.
Texto completoNelson, Cody S., Tori Huffman, Jennifer A. Jenks, Eduardo Cisneros de la Rosa, Guanhua Xie, Nathan Vandergrift, Robert F. Pass, Justin Pollara y Sallie R. Permar. "HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions". Proceedings of the National Academy of Sciences 115, n.º 24 (30 de abril de 2018): 6267–72. http://dx.doi.org/10.1073/pnas.1800177115.
Texto completoHatano, Kazue y Gerald B. Pier. "Complex Serology and Immune Response of Mice to Variant High-Molecular-Weight O Polysaccharides Isolated fromPseudomonas aeruginosa Serogroup O2 Strains". Infection and Immunity 66, n.º 8 (1 de agosto de 1998): 3719–26. http://dx.doi.org/10.1128/iai.66.8.3719-3726.1998.
Texto completoYahalom-Ronen, Yfat, Noam Erez, Morly Fisher, Hadas Tamir, Boaz Politi, Hagit Achdout, Sharon Melamed et al. "Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera". Vaccines 10, n.º 2 (14 de febrero de 2022): 291. http://dx.doi.org/10.3390/vaccines10020291.
Texto completoCarter, Donald M., Christopher A. Darby, Bradford C. Lefoley, Corey J. Crevar, Timothy Alefantis, Raymond Oomen, Stephen F. Anderson et al. "Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses". Journal of Virology 90, n.º 9 (24 de febrero de 2016): 4720–34. http://dx.doi.org/10.1128/jvi.03152-15.
Texto completoGreaney, Allison J., Rachel T. Eguia, Tyler N. Starr, Khadija Khan, Nicholas Franko, Jennifer K. Logue, Sandra M. Lord et al. "The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes". PLOS Pathogens 18, n.º 6 (29 de junio de 2022): e1010592. http://dx.doi.org/10.1371/journal.ppat.1010592.
Texto completodel Valle, Jorge Reyes, Patricia Devaux, Gregory Hodge, Nicholas J. Wegner, Michael B. McChesney y Roberto Cattaneo. "A Vectored Measles Virus Induces Hepatitis B Surface Antigen Antibodies While Protecting Macaques against Measles Virus Challenge". Journal of Virology 81, n.º 19 (18 de julio de 2007): 10597–605. http://dx.doi.org/10.1128/jvi.00923-07.
Texto completoGalula, Jedhan U., Chung-Yu Yang, Brent S. Davis, Gwong-Jen J. Chang y Day-Yu Chao. "Cross-reactivity reduced dengue virus 2 vaccine has no cross-protection against heterotypic dengue viruses". Future Virology 15, n.º 2 (febrero de 2020): 79–90. http://dx.doi.org/10.2217/fvl-2019-0115.
Texto completoMichon, Pascal, Tresa Fraser y John H. Adams. "Naturally Acquired and Vaccine-Elicited Antibodies Block Erythrocyte Cytoadherence of the Plasmodium vivaxDuffy Binding Protein". Infection and Immunity 68, n.º 6 (1 de junio de 2000): 3164–71. http://dx.doi.org/10.1128/iai.68.6.3164-3171.2000.
Texto completoWang, Hongye, Zengshuai Wang, Liang Ma, Xiaoyong Zhu, Bingxiang Li, Yuhang Huang, Jingwen Li, Ming Sun, Li Shi y Yufeng Yao. "S Trimer Derived from SARS-CoV-2 B.1.351 and B.1.618 Induced Effective Immune Response against Multiple SARS-CoV-2 Variants". Vaccines 11, n.º 1 (16 de enero de 2023): 193. http://dx.doi.org/10.3390/vaccines11010193.
Texto completoChen, Shing C., David H. Jones, Ellen F. Fynan, Graham H. Farrar, J. Christopher S. Clegg, Harry B. Greenberg y John E. Herrmann. "Protective Immunity Induced by Oral Immunization with a Rotavirus DNA Vaccine Encapsulated in Microparticles". Journal of Virology 72, n.º 7 (1998): 5757–61. http://dx.doi.org/10.1128/jvi.72.7.5757-5761.1998.
Texto completoLijeskić, Olivera, Ivana Klun, Marija Stamenov Djaković, Nenad Gligorić, Tijana Štajner, Jelena Srbljanović y Olgica Djurković-Djaković. "Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report". Vaccines 9, n.º 9 (17 de septiembre de 2021): 1031. http://dx.doi.org/10.3390/vaccines9091031.
Texto completo